Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form.~* Male or non-pregnant, non-lactating female, ≥ 18 years.~* Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk or arms.~* nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth.~* Willing and able to participate in the trial as an outpatient and comply with all trial requirements.~Exclusion Criteria:~* nBCC located close to or at mouth or eyes.~* Patients who have had an organ transplant.~* Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV), known thyroid abnormalities, known depression.~* An open wound or an infection in treatment area.~* Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the treatment or surrounding area that might impair trial assessments.~* Evidence of an active infection or systemic cancer.~* Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle pain, chills) within a week before start of the trial.~* Known allergy or hypersensitivity to any of the trial gel ingredients.~* Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., renal or hepatic disease).~* Current alcohol abuse or chemical dependency as assessed by the investigator.~* Patient who is detained or committed to an institution by a law court or by legal authorities.~* Participation in another clinical trial within one month before start of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.06% Resiquimod Gel - A (Type: EXPERIMENTAL): * 60 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
- 0.06% Resiquimod Gel - B (Type: EXPERIMENTAL): * 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
- 0.06% Resiquimod Gel - C (Type: EXPERIMENTAL): * 100 mg gel~* Once daily prior to normal sleeping hours~* 5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~* The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).